Loading...
XNYS
WST
Market cap16bUSD
Jul 10, Last price  
229.23USD
1D
1.35%
1Q
8.79%
Jan 2017
170.22%
Name

West Pharmaceutical Services Inc

Chart & Performance

D1W1MN
P/E
33.43
P/S
5.69
EPS
6.86
Div Yield, %
0.26%
Shrs. gr., 5y
-0.46%
Rev. gr., 5y
9.48%
Revenues
2.89b
-1.92%
699,700,000913,300,0001,020,100,0001,051,100,0001,055,700,0001,104,700,0001,192,300,0001,266,400,0001,368,400,0001,421,400,0001,399,800,0001,509,100,0001,599,100,0001,717,400,0001,839,900,0002,146,900,0002,831,600,0002,886,900,0002,949,800,0002,893,200,000
Net income
493m
-16.97%
45,600,00067,100,00070,700,00086,000,00072,600,00065,300,00075,500,00080,700,000112,300,000127,100,00095,600,000143,600,000150,700,000206,900,000241,700,000346,200,000661,800,000585,900,000593,400,000492,700,000
CFO
653m
-15.85%
85,600,000143,800,000129,200,000135,000,000137,700,000138,300,000130,700,000187,400,000220,500,000182,900,000212,400,000219,400,000263,300,000288,600,000367,200,000472,500,000584,000,000724,000,000776,500,000653,400,000
Dividend
Jul 30, 20250.21 USD/sh
Earnings
Jul 23, 2025

Profile

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
IPO date
Jul 27, 1923
Employees
10,700
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,893,200
-1.92%
2,949,800
2.18%
2,886,900
1.95%
Cost of revenue
1,963,800
1,889,000
1,809,200
Unusual Expense (Income)
NOPBT
929,400
1,060,800
1,077,700
NOPBT Margin
32.12%
35.96%
37.33%
Operating Taxes
107,500
122,300
114,700
Tax Rate
11.57%
11.53%
10.64%
NOPAT
821,900
938,500
963,000
Net income
492,700
-16.97%
593,400
1.28%
585,900
-11.47%
Dividends
(59,100)
(57,000)
(54,100)
Dividend yield
0.24%
0.21%
0.30%
Proceeds from repurchase of equity
(566,600)
(451,200)
(194,000)
BB yield
2.35%
1.70%
1.09%
Debt
Debt current
17,900
169,400
18,200
Long-term debt
384,100
259,500
408,700
Deferred revenue
2,100
Other long-term liabilities
105,800
106,700
96,800
Net debt
(284,700)
(635,000)
(672,300)
Cash flow
Cash from operating activities
653,400
776,500
724,000
CAPEX
(377,000)
(362,000)
(284,600)
Cash from investing activities
(378,700)
(368,700)
(288,200)
Cash from financing activities
(622,600)
(459,600)
(293,600)
FCF
688,100
602,000
741,500
Balance
Cash
484,600
853,900
894,300
Long term investments
202,100
210,000
204,900
Excess cash
542,040
916,410
954,855
Stockholders' equity
3,717,300
3,398,400
2,823,600
Invested Capital
2,548,360
2,397,990
2,108,345
ROIC
33.23%
41.65%
48.05%
ROCE
29.88%
31.88%
35.02%
EV
Common stock shares outstanding
73,700
75,300
75,800
Price
327.56
-6.97%
352.12
49.62%
235.35
-49.82%
Market cap
24,141,172
-8.95%
26,514,636
48.63%
17,839,530
-50.15%
EV
23,856,472
25,879,636
17,167,230
EBITDA
1,084,800
1,198,100
1,198,300
EV/EBITDA
21.99
21.60
14.33
Interest
3,000
9,000
7,900
Interest/NOPBT
0.32%
0.85%
0.73%